Clinical Trials for Ovarian Cancer

A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-021 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with ECOG 0–1 and measurable advanced HR+/HER2− breast cancer or selected CCNE1-amplified solid tumors receive oral AVZO-021, an investigational CDK2 inhibitor, alone or in cohort-specific combinations. Combinations include endocrine therapy, CDK4/6 inhibitors, sacituzumab govitecan, or carboplatin; eligibility and prior-treatment requirements vary by cohort.

ClinicalTrials.gov ID: NCT05867251

A Phase I, Multicentre, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced, measurable solid tumors and ECOG performance status 0–2 receive intravenous DM002 every 21 days in dose-escalation or expansion cohorts. DM002 is an investigational bispecific antibody–drug conjugate targeting MUC1 and HER3 with a topoisomerase I inhibitor payload; patients previously treated with a topoisomerase I–payload ADC are generally excluded.

ClinicalTrials.gov ID: NCT06751329

A Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6750, a CD8 Guided IL-2 Agent Alone and in Combination With Other Anti-cancer Agents in Participants With Select Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 and selected advanced or metastatic solid tumors receive AZD6750, an investigational CD8-guided IL-2 agent designed to preferentially stimulate CD8-positive T cells. A separate cohort of patients with stage IV NSCLC receives AZD6750 plus rilvegostomig, an investigational PD-1/TIGIT bispecific antibody.

ClinicalTrials.gov ID: NCT07115043

A Phase 1, First in Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with CLDN6-positive platinum-resistant or refractory ovarian cancer, or advanced testicular or endometrial cancer, receive weekly CTIM-76. This investigational bispecific antibody binds CLDN6 on tumor cells and CD3 on T cells to direct T-cell killing.

ClinicalTrials.gov ID: NCT06515613

A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 in Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This study enrolls patients with CLDN6-positive advanced ovarian, fallopian tube, peritoneal, or endometrial cancer or germ cell tumors that have progressed after standard therapy. Patients receive intravenous or subcutaneous XmAb541, a bispecific antibody that binds CLDN6 on tumor cells and CD3 on T cells.

ClinicalTrials.gov ID: NCT06276491

A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN00-3694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent clear cell or endometrioid ovarian cancer or clear cell or grade 1 endometrioid endometrial cancer after 1–3 prior cytotoxic regimens receive oral tuvusertib, an ATR inhibitor, plus oral ZEN-3694, a BET inhibitor. Dose escalation also permits platinum-resistant high-grade serous ovarian cancer; expansion enrolls separate ARID1A-altered and wild-type cohorts.

ClinicalTrials.gov ID: NCT05950464

A Prospective Randomized Trial of Acute Normovolemic Hemodilution (ANH) in Patients Undergoing Cytoreductive Surgery for Ovarian Cancer

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

TrialFetch AI summary: Adults with suspected or confirmed stage IIIC–IV epithelial ovarian, fallopian tube, or primary peritoneal cancer undergoing primary or interval cytoreductive laparotomy (BLOODS ≥2, Hgb ≥10 g/dL) are randomized to intraoperative acute normovolemic hemodilution (autologous whole-blood collection with crystalloid/colloid replacement and reinfusion) versus standard intraoperative care. The trial tests whether ANH reduces perioperative allogeneic red blood cell transfusion within 30 days.

ClinicalTrials.gov ID: NCT06290193

Administration of T Cells Expressing B7-H3 Specific Chimeric Antigen Receptors (CAR) and Containing the Inducible Caspase 9 Safety Switch in Subjects With Recurrent Platinum Resistant Epithelial Ovarian Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer after at least two prior regimens receive cyclophosphamide/fludarabine lymphodepletion followed by intraperitoneal autologous CAR-T cells targeting B7-H3. The cells carry an inducible caspase-9 safety switch that can be activated with rimiducid for serious toxicity.

ClinicalTrials.gov ID: NCT06305299

Phase I Clinical Trial of Autologous B7-H3 Chimeric Receptor (CAR) T Cells in Adults With Recurrent, Platinum Resistant Ovarian Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable recurrent ovarian carcinoma that is platinum-refractory or recurred within 6 months of platinum therapy after at least one platinum-based regimen receive autologous CAR T cells targeting B7-H3 (CD276). Cells are infused intraperitoneally for eligible peritoneum-confined disease or intravenously for disease outside the peritoneum or when intraperitoneal delivery is unsuitable.

ClinicalTrials.gov ID: NCT06646627

A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Relapsed After Prior Platinum-based Chemotherapy

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This study enrolls patients with measurable relapsed high-grade serous ovarian, primary peritoneal, or fallopian tube cancer after 1–3 prior lines of therapy. Patients with platinum-sensitive disease receive raludotatug deruxtecan, an investigational CDH6-targeting antibody–drug conjugate that delivers a topoisomerase I inhibitor, with carboplatin or paclitaxel; those with platinum-resistant disease receive it with bevacizumab.

ClinicalTrials.gov ID: NCT06843447